Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyvo

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on CLL

Spotlight on CLLAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in...

Medscape Education Global

- PMLiVE

BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial

Results presented at EHA2021 virtual congress showed an improved overall response rate for Brukinsa of 78.3%

Roche Basel Switzerland

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

At 30 months post-treatment, 26.9% of Venclyxto-treated patients had undetectable minimal residual disease

- PMLiVE

AstraZeneca’s Calquence impresses in previously untreated CLL

Takes the fight to AbbVie/J&J’s Imbruvica

- PMLiVE

Mega-mergers dominate as buoyant markets lift biopharma

BridgeBio records biggest flotation in H1

- PMLiVE

FDA will maintain the pace, vows Woodcock, but warns of skills gap

Top official unconcerned by dip in approval rate

Roche - Basel

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

- PMLiVE

Venclexta plus Gazyva approval adds to non-chemo options in CLL

Joins Imbruvica combo in front line use

- PMLiVE

Merck claims key FDA okay for Bavencio in kidney cancer

Will help boost underwhelming revenues

Eli Lilly HQ

Lilly scores FDA okay for Cyramza in liver cancer

Approved as second line treatment after Bayer’s Nexavar

- PMLiVE

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links